PPARα agonist 5

• Description :

  PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM) . PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM) . PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia[1].

• UNSPSC :

  12352005

• Target :

  Phosphatase; PPAR

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Metabolic Disease; Cardiovascular Disease

• Smiles :

  O=C(O)[C@@](C1=CC=CC=C1)(C)OC(C=C2)=CC=C2C3=C(C=CC=C4)C4=CC=C3

• Molecular Formula :

  C25H20O3

• Molecular Weight :

  368.42

• References & Citations :

  [1]Laghezza A, et al. A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model. Eur J Med Chem. 2025 May 5;289:117494.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PPARα; PPARγ; PPARδ